Prevention and Management of Bleeding Episodes in Children with Hemophilia
Ljung, Rolf C.R. LU
(2018)
In Pediatric Drugs
20(5).
p.455-464
- Abstract
Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrations are still necessary. The half-lives of these products have now been extended (EHL) by fusion with albumin, the Fc-portion of IgG, or by being PEGylated. This has been very successful for EHL-FIX, with 3–5 times longer half-life, and to a lesser degree for EHL-FVIII with a half-life extension of only 1.5 times the conventional products.... (More)
Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrations are still necessary. The half-lives of these products have now been extended (EHL) by fusion with albumin, the Fc-portion of IgG, or by being PEGylated. This has been very successful for EHL-FIX, with 3–5 times longer half-life, and to a lesser degree for EHL-FVIII with a half-life extension of only 1.5 times the conventional products. New treatment principles using FVIII mimetics or monoclonal antibodies that rebalance the pro- and anti-coagulation system by interfering with production of anti-thrombin or tissue factor pathway inhibitor have the benefits of long-lasting activity, subcutaneous administration, and being useful in patients both with and without neutralizing antibodies. As the ultimate treatment, recent progress has also been made with gene therapy of both hemophilia A and B.
(Less)
- author
- Ljung, Rolf C.R.
LU
- organization
- publishing date
- 2018-08-21
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Drugs
- volume
- 20
- issue
- 5
- pages
- 455 - 464
- publisher
- Adis International
- external identifiers
-
- scopus:85051834700
- pmid:30128815
- ISSN
- 1174-5878
- DOI
- 10.1007/s40272-018-0307-z
- language
- English
- LU publication?
- yes
- id
- aea5feb2-2b26-47ae-ae8f-fa052b09c00f
- date added to LUP
- 2018-09-12 09:43:55
- date last changed
- 2024-04-15 11:22:05
@article{aea5feb2-2b26-47ae-ae8f-fa052b09c00f,
abstract = {{<p>Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrations are still necessary. The half-lives of these products have now been extended (EHL) by fusion with albumin, the Fc-portion of IgG, or by being PEGylated. This has been very successful for EHL-FIX, with 3–5 times longer half-life, and to a lesser degree for EHL-FVIII with a half-life extension of only 1.5 times the conventional products. New treatment principles using FVIII mimetics or monoclonal antibodies that rebalance the pro- and anti-coagulation system by interfering with production of anti-thrombin or tissue factor pathway inhibitor have the benefits of long-lasting activity, subcutaneous administration, and being useful in patients both with and without neutralizing antibodies. As the ultimate treatment, recent progress has also been made with gene therapy of both hemophilia A and B.</p>}},
author = {{Ljung, Rolf C.R.}},
issn = {{1174-5878}},
language = {{eng}},
month = {{08}},
number = {{5}},
pages = {{455--464}},
publisher = {{Adis International}},
series = {{Pediatric Drugs}},
title = {{Prevention and Management of Bleeding Episodes in Children with Hemophilia}},
url = {{http://dx.doi.org/10.1007/s40272-018-0307-z}},
doi = {{10.1007/s40272-018-0307-z}},
volume = {{20}},
year = {{2018}},
}